
About this episode
The lack of diversity in genomic data has been an issue of growing concern. It threatens to limit the benefits from the massive investment that has been made to date to transform biomedical research, drug development, and the clinical care of patients. We spoke to Jonas Korlach, chief scientific officer of Pacific Biosciences, about the problem, how it’s being addressed, and the role advancing technology can play in gleaning greater insights from the genomes that are analyzed.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Bio Report

Resetting Severe Allergies at Their Cellular Source
The Bio Report
Sep 2, 202633:17pending

Innovating ADCs with Dual Targeting and Smarter Delivery
The Bio Report
Aug 26, 202629:35pending

Targeting the Brain’s Immune System in Alzheimer’s Disease
The Bio Report
Aug 19, 202634:19pending

How Gilead Is Building Durable Oncology and Immunology Franchises
The Bio Report
Aug 12, 202638:31pending